During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

The analysis included hormone receptor and HER2/neu status to define subtypes: HR+ HER2+, HR+ HER2−, HR− HER2+, and HR− HER2− ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

IC50 和靶标：IC50：59 nM (HER2)，92 nM (EGFR) 体外：Neratinib 对其他丝氨酸-苏氨酸激酶没 ... 2 天）抑制显示高水平 HER- 2（3T3/neu、SK-Br-3 和 BT474）并且在既不表达 HER-2 也不表达 EGFR（3T3、MDA-MB-435 和 SW620）的细胞系中活性低得多 [1]< /sup>. Neratinib (0-2 ...

Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented at the ...

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary ...

2 Brain metastases are present in up to 30% of patients with NSCLC with activating HER2 mutations at diagnosis. 3 "These new data could represent positive news in the future treatment of non-small ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Bayer announced encouraging results from the expansion part of the ongoing Phase I/II SOHO-01 study evaluating the safety and preliminary efficacy of BAY 2927088 in advanced HER2-mutant non-small ...

Researchers have developed a new mechanism for predicting the aggressiveness of triple-negative breast cancer (TNBC). This ...